Review article: Thiazolidinediones and heart failure (Q37724501)

22 August 2017

1 reference

title

Review article: Thiazolidinediones and heart failure (English)

1 reference

22 August 2017

0 references

Parminder S Chaggar

1

1 reference

22 August 2017

Steven M Shaw

series ordinal

2

1 reference

22 August 2017

Simon G Williams

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

Diabetes and Vascular Disease Research

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

3

1 reference

22 August 2017

146-152

1 reference

Epidemiology, aetiology, and prognosis of heart failure

22 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Glycemic control and heart failure among adult patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Diabetic cardiomyopathy revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Insulin resistance and its treatment by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Peroxisome proliferator-activated receptor-gamma is involved in the control of renin gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

Patient-important outcomes in diabetes—time for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164109338772

21 January 2018

Identifiers

DOI

10.1177/1479164109338772

1 reference

22 August 2017

1 reference